Multiple Sclerosis Drugs - ASEAN

ASEAN

The ASEAN region is also expected to witness significant growth in the Multiple Sclerosis Drugs market.
By 2024, the revenue in this market is projected to reach US$235.30m.
Furthermore, it is anticipated that the market will experience a steady annual growth rate of 1.84% between 2024 and 2029.
This growth trajectory will lead to a market volume of US$257.70m by 2029.
When compared globally, it is worth noting that United States is expected to generate the highest revenue in the Multiple Sclerosis Drugs market.
In 2024, the projected revenue for the United States alone is an impressive US$11,770.00m.
This indicates the significant market potential and importance of the United States in this market.
The demand for Multiple Sclerosis Drugs in ASEAN countries is steadily increasing due to the rising prevalence of the disease and increasing healthcare infrastructure.

Key regions: France, India, United Kingdom, South Korea, Japan

Market

Region

Region comparison

Currency

Analyst Opinion

The Multiple Sclerosis Drugs market in ASEAN is experiencing growth due to various factors.

Customer preferences: Patients with Multiple Sclerosis in ASEAN countries have a preference for disease-modifying therapies that are effective in reducing the frequency and severity of relapses. They also prefer medications that have a low risk of side effects and are affordable.

Trends in the market: The Multiple Sclerosis Drugs market in ASEAN is witnessing a trend towards the use of oral medications. This is due to the convenience of oral medications compared to injectable medications. Additionally, there is an increasing trend towards the use of biosimilars, which are less expensive alternatives to branded medications.

Local special circumstances: The availability of Multiple Sclerosis Drugs in ASEAN countries varies widely. Countries such as Singapore and Malaysia have a higher availability of drugs compared to countries like Cambodia and Laos. This is due to differences in healthcare infrastructure and regulatory frameworks.

Underlying macroeconomic factors: The Multiple Sclerosis Drugs market in ASEAN is influenced by macroeconomic factors such as healthcare spending, government policies, and population demographics. Countries with higher healthcare spending and supportive government policies tend to have a more developed Multiple Sclerosis Drugs market. Additionally, countries with aging populations are expected to have a higher demand for Multiple Sclerosis Drugs in the future.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.